Alkermes’s Promising Orexin Drug Development Positions Company for Market Leadership
Mizuho Securities analyst Uy Ear has maintained their bullish stance on ALKS stock, giving a Buy rating on September 26. Uy Ear has given his ...
Wire Reddington’s defence claims schizophrenia, Crown argues drug-induced psychosis
A forensic psychiatrist for the defence in a murder trial believes the accused Wire Reddington was suffering from ...
Medical News Today14h
Seroquel: Pregnancy, breastfeeding, and birth control information
Seroquel is a brand-name oral tablet that doctors prescribe for schizophrenia and certain types of bipolar disorder. It ...
Zacks.com on MSN15h
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
Last week, Bristol Myers BMY obtained FDA approval for a label expansion of its blockbuster immuno oncology drug Opdivo ...
DEA could reclassify marijuana to a less restrictive category – a drug policy expert weighs the pros and cons
Though there are three criteria for Schedule I in the Controlled Substances Act, the DEA in fact relies on only the medical use criterion. This was the basis of the DEA’s proposal to reschedule ...
Labroots2d
FDA approval of novel schizophrenia drug
The recent FDA approval of KarXT (Cobenfy), developed by Karuna Therapeutics (a subsidiary of Bristol Myers Squibb), marks a ...
kffhealthnews2d
Out Of The Trash Bin: How Cobenfy’s Unusual Journey Could Change Pharma
Bristol Myers Squibb's schizophrenia drug, which received FDA approval last week, took a long and winding road to get there. Three decades ago, Eli Lilly developed the drug's forerunner, xanomeline, ...
BioPharma Dive2d
Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney
The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.
Old Drug Repurposed for Schizophrenia Could Reap Alzheimer’s Windfall
Such is the case with newly approved Bristol-Myers Squibb drug Cobenfy. The underlying drug was first studied in Alzheimer’s ...
FiercePharma3d
For Bristol Myers Squibb's newly approved schizophrenia drug, what a long, strange trip it's been
Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers ...
Yale Daily News3d
Yale doctors weigh in on the first FDA-approved schizophrenia drug in nearly 30 years
For the first time in nearly 30 years, the U.S. Food and Drug Administration has approved a new drug treating schizophrenia, ...